Analysis reveals CAR T-cell therapy shows similar efficacy but improved toxicity for adolescents and young adults with NHL, suggesting tailored treatment approaches are needed.
Key Points
CAR T-cell therapy demonstrated comparable efficacy in adolescents and young adults with non-Hodgkin lymphoma.
Progression-free survival rates were 37% in AYAs versus 34% in non-AYAs, with no significant difference.
Observational analysis evaluated efficacy and toxicity profiles among matched cohorts of AYAs and older adults.
This highlights the favorable toxicity profile in AYAs, indicating a need for further research on long-term outcomes.